Biohaven Pharma (BHVN) Misses Q1 EPS by 15c, Revenues Beat

Biohaven Pharma (NYSE: BHVN) reported Q1 EPS of ($2.97), $0.15 worse than the analyst estimate of ($2.82). Revenue for the quarter came in at $43.82 million versus the consensus estimate of $40.63 million.

Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "NURTEC ODT's performance, with its differentiated efficacy and safety profile, continues to be bolstered by overwhelmingly positive patient and provider sentiment to date. We are highly encouraged by the continued success of NURTEC ODT, with net revenues of $43.8 million in the first quarter exceeding expectations."

Dr. Coric added, "In addition to pursuing multiple life-cycle management and also non-migraine indications with our CGRP-antagonist franchise, we continue to make strides in advancing the many programs across our pipeline, recognizing the high unmet need for treatments within our MPO inhibitor and glutamate modulating platforms. The impressive enrollment of verdiperstat in both the MSA trial and the Healey ALS trial is a testament to our commitment to delivering solutions within the neurodegenerative space. We look forward to announcing topline results across multiple assets in our pipeline over the next year."

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• Netskope, Inc. (NTSK) Tops Q1 EPS by 1c, Offers Guidance
• Broadcom (AVGO) Tops Q2 EPS by 5c, Offers Guidance